がんワクチン医薬品パイプライン市場の2030年までの予測： タイプ別、がんタイプ別、技術別、エンドユーザー別、地域別の世界分析

Stratistics MRCによると、世界のがんワクチン医薬品パイプライン市場は2023年に64億6,000万米ドルを占め、予測期間中にCAGR 20.0％で成長し、2030年には231億7,000万米ドルに達すると予測されています。

がんワクチン医薬品パイプラインとは、がんを予防、治療、管理するためのワクチン創出に焦点を当てた研究開発のことです。これらのワクチンは、体内の免疫系を刺激してがん細胞を認識・攻撃させることで作用し、がん治療において標的を絞った侵襲性の低いアプローチを提供する可能性があります。パイプラインには、初期の前臨床研究から臨床試験まで様々な開発段階があり、安全で効果的ながんワクチンを市場に投入することを最終目標としています。

世界保健機関（WHO）によると、がんは世界第2位の死因であり、2018年には推定960万人が死亡しています。

がん罹患率の上昇

より多くの人々ががんの脅威に直面するにつれ、ワクチンのような効果的な予防・治療ソリューションへの需要が急増しています。この緊急性が研究開発への取り組みを促し、科学者たちをワクチン技術の探求、革新、改良に向かわせ、最終的にパイプラインを拡大することで、この増大する世界の健康課題との闘いが期待されています。したがって、こうした要因が市場の成長を加速させています。

複雑な開発プロセス

パイプラインにある多くのがんワクチンは、臨床試験において限定的な有効性しか示さず、がんの予防や治療における有効性への懸念を引き起こしています。また、潜在的な副作用や免疫反応に関する安全性への懸念が、患者やヘルスケア専門家の間にためらいを生んでいます。このような複雑なプロセスは、一部の企業が市場に参入することを躊躇させ、パイプラインの全体的な発展と多様化の妨げとなっています。

併用療法

がんワクチンを化学療法、免疫療法、分子標的治療など、他の確立された治療法と組み合わせることは、がん治療に革命をもたらし、患者の転帰を改善するまたとない機会となります。このアプローチは、治療成績を改善し、副作用を最小化し、患者の生存期間を延長する可能性があります。様々な治療法の相補的な作用機序を活用することで、併用戦略はがんの多面的な性質に対処し、この複雑な疾患との継続的な戦いにおいて、より効果的で個別化された治療アプローチへの道を開くことを目指しています。

規制上のハードル

長い承認プロセスや複雑な臨床試験プロトコルを含む厳しい規制要件は、市場参入を遅らせ、開発コストを増加させる可能性があります。進化する規制ガイドラインや厳しい安全基準を取り巻く不確実性は、がんワクチンの研究開発への投資を抑制する可能性があります。また、地域や管轄区域によって規制基準が異なるため、市場情勢がさらに複雑になり、世界市場への参入が制限される可能性があります。

COVID-19の影響

COVID-19の大流行は、がんの研究開発から資源、注意、資金をそらし、ワクチンの発見や臨床試験の進展を遅らせた。封鎖措置はサプライチェーンを混乱させ、臨床試験を停止させ、潜在的ながんワクチンの進歩を遅らせた。このような挫折にもかかわらず、パンデミックはワクチン開発における技術革新と協力に拍車をかけ、遠隔医療と遠隔臨床試験モニタリングの加速的な導入につながった。

予測期間中、予防ワクチン分野が最大となる見込み

予防ワクチン分野が最大のシェアを占めると推定されます。予防ワクチンは、ある種のがんを引き起こすことが知られている特定の感染因子を標的とすることで、がんの発症を予防することに焦点を当てています。これらのワクチンは、がん発症に関連するウイルスや細菌などの病原体を認識し、破壊するよう免疫系を刺激することで機能します。さらに、これらの発がん性病原体への感染を予防することで、予防ワクチンは関連するがんの発症リスクを低減することを目的としています。

予測期間中、肺がん分野のCAGRが最も高くなる見込み

肺がん分野は、予測期間中に有利な成長を遂げると予測されます。この分野は、肺がんを予防または治療するために特別に設計されたワクチンの開発に焦点を当てています。これらのワクチンは、肺がん細胞に存在する抗原を標的とし、腫瘍細胞に対する身体の免疫反応を引き起こすことを目的としています。肺がんは世界的に重要な健康問題であり、効果的なワクチンの開発は肺がんの負担を軽減し、患者の生存率を向上させることが期待されています。

最大のシェアを占める地域

アジア太平洋地域は、がん有病率の上昇に加え、予防対策に対する意識の高まりと採用の増加により、予測期間中最大の市場シェアを占めました。中国は、その人口の多さ、バイオテクノロジー分野の成長、および好ましい規制政策によって、最大の市場となっています。多くのアジア諸国では規制の枠組みが合理化・効率化されつつあり、新規がんワクチンの開発・承認が促進されています。さらに、同地域の政府はワクチン開発や臨床試験への資金提供を含め、がん研究開発を積極的に支援しています。

CAGRが最も高い地域：

北米は予測期間中、収益性の高い成長が見込まれます。北米はがんの負担が大きく、数種類のがんが地域全体に蔓延しています。このため、効果的な予防法や治療法に対する需要が高まっています。また、この地域は、革新的ながんワクチンの開発に積極的に取り組んでいる大手研究機関、製薬会社、バイオテクノロジー企業を擁しています。政府機関および民間投資家はいずれも、ワクチンプログラムを含むがん研究開発の資金調達に大きく貢献しています。

無料カスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場プレーヤーの包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査情報源
  • 1次調査情報源
  • 2次調査情報源
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 技術分析
• エンドユーザー分析
• 新興市場
• COVID-19の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のがんワクチン医薬品パイプライン市場：タイプ別

• 予防ワクチン
• 治療ワクチン

第6章 世界のがんワクチン医薬品パイプライン市場：がんタイプ別

• 乳がん
• 前立腺がん
• 肺がん
• 大腸がん
• その他のがんタイプ

第7章 世界のがんワクチン医薬品パイプライン市場：技術別

• 組み換えワクチン
• ウイルスベクターワクチン
• 全細胞ワクチン
• DNAワクチン
• その他の技術

第8章 世界のがんワクチン医薬品パイプライン市場：エンドユーザー別

• 病院
• 外来診療センター

第9章 世界のがんワクチン医薬品パイプライン市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第10章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品発売
• 事業拡大
• その他の主要戦略

第11章 企業プロファイリング

• AstraZeneca
• F. Hoffmann-La Roche
• Merck & Co.
• Pfizer
• Johnson & Johnson
• Sanofi
• GlaxoSmithKline（GSK）
• Moderna
• Novartis
• Bristol-Myers Squibb
• BioNTech
• Genentech
• Bavarian Nordic
• Takeda Pharmaceuticals
• OncoGenex Pharmaceuticals
• Northwest Biotherapeutics
• Vaxil Bio
• Immunomic Therapeutics
• Transgene
• Arbor Pharmaceuticals

List of Tables

• Table 1 Global Cancer Vaccines Drug Pipeline Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
• Table 3 Global Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
• Table 4 Global Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
• Table 5 Global Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 6 Global Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 7 Global Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 8 Global Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 9 Global Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 10 Global Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 11 Global Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
• Table 12 Global Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
• Table 13 Global Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
• Table 14 Global Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
• Table 15 Global Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
• Table 16 Global Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 17 Global Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
• Table 18 Global Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
• Table 19 Global Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 20 North America Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
• Table 21 North America Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
• Table 22 North America Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
• Table 23 North America Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
• Table 24 North America Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 25 North America Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 26 North America Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 27 North America Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 28 North America Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 29 North America Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 30 North America Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
• Table 31 North America Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
• Table 32 North America Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
• Table 33 North America Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
• Table 34 North America Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
• Table 35 North America Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 36 North America Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
• Table 37 North America Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
• Table 38 North America Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 39 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
• Table 40 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
• Table 41 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
• Table 42 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
• Table 43 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 44 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 45 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 46 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 47 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 48 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 49 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
• Table 50 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
• Table 51 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
• Table 52 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
• Table 53 Europe Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
• Table 54 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 55 Europe Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
• Table 56 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
• Table 57 Europe Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 58 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
• Table 59 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
• Table 60 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
• Table 61 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
• Table 62 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 63 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 64 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 65 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 66 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 67 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 68 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
• Table 69 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
• Table 70 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
• Table 71 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
• Table 72 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
• Table 73 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 74 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
• Table 75 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
• Table 76 Asia Pacific Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 77 South America Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
• Table 78 South America Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
• Table 79 South America Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
• Table 80 South America Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
• Table 81 South America Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 82 South America Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 83 South America Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 84 South America Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 85 South America Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 86 South America Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 87 South America Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
• Table 88 South America Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
• Table 89 South America Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
• Table 90 South America Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
• Table 91 South America Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
• Table 92 South America Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 93 South America Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
• Table 94 South America Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
• Table 95 South America Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)
• Table 96 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Country (2021-2030) ($MN)
• Table 97 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Type (2021-2030) ($MN)
• Table 98 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Prophylactic Vaccine (2021-2030) ($MN)
• Table 99 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Therapeutic Vaccine (2021-2030) ($MN)
• Table 100 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Cancer Type (2021-2030) ($MN)
• Table 101 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Breast Cancer (2021-2030) ($MN)
• Table 102 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Prostate Cancer (2021-2030) ($MN)
• Table 103 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Lung Cancer (2021-2030) ($MN)
• Table 104 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
• Table 105 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Other Cancer Types (2021-2030) ($MN)
• Table 106 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Technology (2021-2030) ($MN)
• Table 107 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
• Table 108 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Viral Vector Vaccines (2021-2030) ($MN)
• Table 109 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Whole-Cell Vaccines (2021-2030) ($MN)
• Table 110 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By DNA Vaccines (2021-2030) ($MN)
• Table 111 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Other Technologies (2021-2030) ($MN)
• Table 112 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By End User (2021-2030) ($MN)
• Table 113 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Hospital (2021-2030) ($MN)
• Table 114 Middle East & Africa Cancer Vaccines Drug Pipeline Market Outlook, By Ambulatory Care Centers (2021-2030) ($MN)

According to Stratistics MRC, the Global Cancer Vaccines Drug Pipeline Market is accounted for $6.46 billion in 2023 and is expected to reach $23.17 billion by 2030 growing at a CAGR of 20.0% during the forecast period. The Cancer Vaccines Drug Pipeline is the ongoing research and development efforts focused on creating vaccines for preventing, treating, or managing cancer. These vaccines work by stimulating the body's immune system to recognize and attack cancer cells, offering a potentially targeted and less invasive approach to cancer treatment. The pipeline includes various stages of development, from early preclinical research to clinical trials, with the ultimate goal of bringing safe and effective cancer vaccines to market.

According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018.

Market Dynamics:

Driver:

Rising incidence of cancer

As more individuals face the threat of cancer, the demand for effective preventative and therapeutic solutions like vaccines surges. This urgency incentivizes research and development efforts, pushing scientists to explore, innovate, and refine vaccine technologies, ultimately expanding the pipeline with the hope of combating this growing global health challenge. Therefore, these factors are accelerating market growth.

Restraint:

Complex development process

Many cancer vaccines in the pipeline demonstrate limited efficacy in clinical trials, raising concerns about their effectiveness in preventing or treating cancer. Also, safety concerns regarding potential side effects and immune reactions can create hesitancy among patients and healthcare professionals. The complex process discourages some companies from entering the market, hindering the overall development and diversification of the pipeline.

Opportunity:

Combination therapies

Integrating cancer vaccines with other established therapies, such as chemotherapy, immunotherapy, or targeted therapies, presents a unique opportunity to revolutionize cancer treatment and improve patient outcomes. This approach holds promise for improving treatment outcomes, minimising adverse effects, and potentially extending patient survival. By leveraging the complementary mechanisms of action of various therapies, combination strategies aim to address the multifaceted nature of cancer, paving the way for more effective and personalised treatment approaches in the ongoing battle against this complex disease.

Threat:

Regulatory hurdles

Stringent regulatory requirements, including lengthy approval processes and complex clinical trial protocols, can delay market entry and increase development costs. Uncertainty surrounding evolving regulatory guidelines and stringent safety standards may deter investment in cancer vaccine research and development. Also, varying regulatory standards across different regions and jurisdictions further complicate the market landscape, potentially limiting global market access.

Covid-19 Impact

The COVID-19 pandemic has diverted resources, attention, and funding away from cancer research and development, slowing down progress in vaccine discovery and clinical trials. Lockdown measures disrupted supply chains and halted clinical trials, delaying the advancement of potential cancer vaccines. Despite these setbacks, the pandemic has also spurred innovation and collaboration in vaccine development, leading to the accelerated adoption of telemedicine and remote clinical trial monitoring, which may benefit the cancer vaccine pipeline market in the long term.

The prophylactic vaccine segment is expected to be the largest during the forecast period

The prophylactic vaccine segment is estimated to hold the largest share. The prophylactic vaccine focuses on preventing the development of cancer by targeting specific infectious agents known to cause certain types of cancer. These vaccines work by stimulating the immune system to recognise and destroy pathogens, such as viruses or bacteria that are linked to cancer development. Moreover, by preventing infection with these carcinogenic agents, prophylactic vaccines aim to reduce the risk of developing associated cancers.

The lung cancer segment is expected to have the highest CAGR during the forecast period

The lung cancer segment is anticipated to have lucrative growth during the forecast period. This segment focuses on the development of vaccines specifically designed to prevent or treat lung cancer. These vaccines target antigens present in lung cancer cells, aiming to trigger the body's immune response against tumour cells. With lung cancer being a significant global health concern, the development of effective vaccines holds promise for reducing its burden and improving patient survival rates.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to the rising prevalence of cancer in the region, coupled with increasing awareness and adoption of preventive measures. China is the largest market, driven by its large population, growing biotechnology sector, and favourable regulatory policies. Regulatory frameworks in many Asian countries are becoming more streamlined and efficient, facilitating the development and approval of new cancer vaccines. Moreover, governments in the region are actively supporting cancer research and development, including funding for vaccine development and clinical trials.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America faces a significant burden of cancer, with several types prevalent across the region. This drives demand for effective preventive and therapeutic options. Also, the region boasts leading research institutions, pharmaceutical companies, and biotechnology firms actively engaged in developing innovative cancer vaccines. Both government agencies and private investors significantly contribute to funding cancer research and development, including vaccine programs.

Key players in the market

Some of the key players in the Cancer Vaccines Drug Pipeline Market include AstraZeneca, F. Hoffmann-La Roche, Merck & Co., Pfizer, Johnson & Johnson, Sanofi, GlaxoSmithKline (GSK), Moderna, Novartis, Bristol-Myers Squibb, BioNTech, Genentech, Bavarian Nordic, Takeda Pharmaceuticals, OncoGenex Pharmaceuticals, Northwest Biotherapeutics, Vaxil Bio, Immunomic Therapeutics, Transgene and Arbor Pharmaceuticals.

Key Developments:

In February 2024, AstraZeneca unveils successes in treatment of lung cancer, with its leading drug slowing progression of the disease at an early stage. AstraZeneca also announced that the drug had been approved to be used alongside chemotherapy in the US to treat the same form of lung cancer at an advanced stage, where it extended progression-free survival by almost nine months.

In December 2023, AstraZeneca ties up with AI Biologics Company to develop cancer drug. The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy - a leading focus of Anglo-Swedish drugmaker AstraZeneca.

Types Covered:

• Prophylactic Vaccine
• Therapeutic Vaccine

Cancer Types Covered:

• Breast Cancer
• Prostate Cancer
• Lung Cancer
• Colorectal Cancer
• Other Cancer Types

Technologies Covered:

• Recombinant Vaccines
• Viral Vector Vaccines
• Whole-Cell Vaccines
• DNA Vaccines
• Other Technologies

End Users Covered:

• Hospital
• Ambulatory Care Centers

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Cancer Vaccines Drug Pipeline Market, By Type

• 5.1 Introduction
• 5.2 Prophylactic Vaccine
• 5.3 Therapeutic Vaccine

6 Global Cancer Vaccines Drug Pipeline Market, By Cancer Type

• 6.1 Introduction
• 6.2 Breast Cancer
• 6.3 Prostate Cancer
• 6.4 Lung Cancer
• 6.5 Colorectal Cancer
• 6.6 Other Cancer Types

7 Global Cancer Vaccines Drug Pipeline Market, By Technology

• 7.1 Introduction
• 7.2 Recombinant Vaccines
• 7.3 Viral Vector Vaccines
• 7.4 Whole-Cell Vaccines
• 7.5 DNA Vaccines
• 7.6 Other Technologies

8 Global Cancer Vaccines Drug Pipeline Market, By End User

• 8.1 Introduction
• 8.2 Hospital
• 8.3 Ambulatory Care Centers

9 Global Cancer Vaccines Drug Pipeline Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 AstraZeneca
• 11.2 F. Hoffmann-La Roche
• 11.3 Merck & Co.
• 11.4 Pfizer
• 11.5 Johnson & Johnson
• 11.6 Sanofi
• 11.7 GlaxoSmithKline (GSK)
• 11.8 Moderna
• 11.9 Novartis
• 11.10 Bristol-Myers Squibb
• 11.11 BioNTech
• 11.12 Genentech
• 11.13 Bavarian Nordic
• 11.14 Takeda Pharmaceuticals
• 11.15 OncoGenex Pharmaceuticals
• 11.16 Northwest Biotherapeutics
• 11.17 Vaxil Bio
• 11.18 Immunomic Therapeutics
• 11.19 Transgene
• 11.20 Arbor Pharmaceuticals